Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Lymphomatoid papulosis

Marshall E Kadin, MD
Section Editor
John A Zic, MD
Deputy Editor
Rosamaria Corona, MD, DSc


Lymphomatoid papulosis (LyP) is a recurrent, self-healing papulonodular skin eruption with histologic features of a CD30+ lymphoid proliferation of atypical T cells [1,2]. LyP is part of the group of cutaneous CD30+ lymphoproliferative disorders (LPDs) that includes primary cutaneous anaplastic large cell lymphoma (PC-ALCL) and borderline CD30+ lesions. Clinicopathologic correlation is essential for establishing the diagnosis of LyP, as there are many clinical and histologic mimics of LyP.

LyP is characterized by a chronic course, lasting years or decades. Grouped or generalized papules and nodules develop and spontaneously regress over weeks to months (picture 3D). Patients with LyP have an excellent prognosis, although they are at increased risk of developing a second cutaneous or nodal lymphoma, such as mycosis fungoides, PC-ALCL, or Hodgkin lymphoma.

This topic will discuss the clinical presentation, diagnosis, and treatment of LyP. Other cutaneous T cell lymphomas are discussed separately.

(See "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma".)

(See "Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: May 23, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant. Arch Dermatol 1968; 97:23.
  2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.
  3. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95:3653.
  4. Assaf C, Gellrich S, Steinhoff M, et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges 2007; 5:662.
  5. Kunishige JH, McDonald H, Alvarez G, et al. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol 2009; 34:576.
  6. Gomez ML. First World Congress on Cutaneous Lymphomas, Chicago, IL Sept 23-26, 2010.
  7. Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol 2013; 37:1173.
  8. Wang HH, Myers T, Lach LJ, et al. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer 1999; 86:1240.
  9. Kadin ME, Vonderheid EC, Weiss LM. Absence of Epstein-Barr viral RNA in lymphomatoid papulosis. J Pathol 1993; 170:145.
  10. Peters K, Knoll JH, Kadin ME. Cytogenetic findings in regressing skin lesions of lymphomatoid papulosis. Cancer Genet Cytogenet 1995; 80:13.
  11. Kempf W, Kadin ME, Kutzner H, et al. Lymphomatoid papulosis and human herpesviruses--A PCR-based evaluation for the presence of human herpesvirus 6, 7 and 8 related herpesviruses. J Cutan Pathol 2001; 28:29.
  12. Kempf W, Kadin ME, Dvorak AM, et al. Endogenous retroviral elements, but not exogenous retroviruses, are detected in CD30-positive lymphoproliferative disorders of the skin. Carcinogenesis 2003; 24:301.
  13. Ponti R, Bergallo M, Costa C, et al. Human herpesvirus 7 detection by quantitative real time polymerase chain reaction in primary cutaneous T-cell lymphomas and healthy subjects: lack of a pathogenic role. Br J Dermatol 2008; 159:1131.
  14. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8:11.
  15. Wright CW, Duckett CS. The aryl hydrocarbon nuclear translocator alters CD30-mediated NF-kappaB-dependent transcription. Science 2009; 323:251.
  16. Franchina M, Kadin ME, Abraham LJ. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. Cancer Epidemiol Biomarkers Prev 2005; 14:1322.
  17. Steinhoff M, Hummel M, Anagnostopoulos I, et al. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. Blood 2002; 100:578.
  18. Humme D, Lukowsky A, Steinhoff M, et al. Dominance of nonmalignant T-cell clones and distortion of the TCR repertoire in the peripheral blood of patients with cutaneous CD30+ lymphoproliferative disorders. J Invest Dermatol 2009; 129:89.
  19. Weiss LM, Wood GS, Trela M, et al. Clonal T-cell populations in lymphomatoid papulosis. Evidence of a lymphoproliferative origin for a clinically benign disease. N Engl J Med 1986; 315:475.
  20. Schultz JC, Granados S, Vonderheid EC, Hwang ST. T-cell clonality of peripheral blood lymphocytes in patients with lymphomatoid papulosis. J Am Acad Dermatol 2005; 53:152.
  21. Miquel J, Fraitag S, Hamel-Teillac D, et al. Lymphomatoid papulosis in children: a series of 25 cases. Br J Dermatol 2014; 171:1138.
  22. Davis TH, Morton CC, Miller-Cassman R, et al. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med 1992; 326:1115.
  23. Chott A, Vonderheid EC, Olbricht S, et al. The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol 1996; 106:696.
  24. Amagai M, Kawakubo Y, Tsuyuki A, Harada R. Lymphomatoid papulosis followed by Ki-1 positive anaplastic large cell lymphoma: proliferation of a common T-cell clone. J Dermatol 1995; 22:743.
  25. Assaf C, Hummel M, Dippel E, et al. Common clonal T-cell origin in a patient with T-prolymphocytic leukaemia and associated cutaneous T-cell lymphomas. Br J Haematol 2003; 120:488.
  26. Zackheim HS, Jones C, Leboit PE, et al. Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality. J Am Acad Dermatol 2003; 49:620.
  27. Basarab T, Fraser-Andrews EA, Orchard G, et al. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol 1998; 139:630.
  28. Volkenandt M, Bertino JR, Shenoy BV, et al. Molecular evidence for a clonal relationship between lymphomatoid papulosis and Ki-1 positive large cell anaplastic lymphoma. J Dermatol Sci 1993; 6:121.
  29. Wood GS, Crooks CF, Uluer AZ. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol 1995; 105:51.
  30. Gallardo F, Costa C, Bellosillo B, et al. Lymphomatoid papulosis associated with mycosis fungoides: clinicopathological and molecular studies of 12 cases. Acta Derm Venereol 2004; 84:463.
  31. Kadin ME, Cavaille-Coll MW, Gertz R, et al. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci U S A 1994; 91:6002.
  32. Schiemann WP, Pfeifer WM, Levi E, et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood 1999; 94:2854.
  33. Willemze R, Meyer CJ, Van Vloten WA, Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol 1982; 107:131.
  34. DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996; 87:3437.
  35. Mathas S, Kreher S, Meaburn KJ, et al. Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A 2009; 106:5831.
  36. Braun FK, Hirsch B, Al-Yacoub N, et al. Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP. J Invest Dermatol 2010; 130:826.
  37. Kikuchi A, Nishikawa T. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Arch Dermatol 1997; 133:829.
  38. Greisser J, Doebbeling U, Roos M, et al. Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol 2005; 14:380.
  39. Paulli M, Berti E, Boveri E, et al. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 1998; 29:1223.
  40. Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol 2001; 145:928.
  41. Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol 2004; 140:306.
  42. Wieser I, Oh CW, Talpur R, Duvic M. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol 2016; 74:59.
  43. Knaus PI, Lindemann D, DeCoteau JF, et al. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 1996; 16:3480.
  44. de Souza A, el-Azhary RA, Camilleri MJ, et al. In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients. J Am Acad Dermatol 2012; 66:928.
  45. Cordel N, Tressières B, D'Incan M, et al. Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. Oncologist 2016; 21:76.
  46. Kempf W, Levi E, Kamarashev J, et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol 2002; 29:295.
  47. Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol 2012; 132:703.
  48. Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol 2010; 34:1168.
  49. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155:483.
  50. Kempf W, Kazakov DV, Schärer L, et al. Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas. Am J Surg Pathol 2013; 37:1.
  51. Kempf W, Kazakov DV, Baumgartner HP, Kutzner H. Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings. J Am Acad Dermatol 2013; 68:809.
  52. Kadin M, Nasu K, Sako D, et al. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. Am J Pathol 1985; 119:315.
  53. Kummer JA, Vermeer MH, Dukers D, et al. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 1997; 109:636.
  54. Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 2006; 33 Suppl 1:58.
  55. Sharaf MA, Romanelli P, Kirsner R, Miteva M. Angioinvasive lymphomatoid papulosis: another case of a newly described variant. Am J Dermatopathol 2014; 36:e75.
  56. Chimenti S, Fargnoli MC, Pacifico A, Peris K. Mucosal involvement in a patient with lymphomatoid papulosis. J Am Acad Dermatol 2001; 44:339.
  57. Kato N, Tomita Y, Yoshida K, Hisai H. Involvement of the tongue by lymphomatoid papulosis. Am J Dermatopathol 1998; 20:522.
  58. Benslama L, Andre CV, Charlotte F, et al. [Mucosal lymphomatoid papulosis: 2 cases]. Rev Stomatol Chir Maxillofac Chir Orale 2015; 116:111.
  59. Heald P, Subtil A, Breneman D, Wilson LD. Persistent agmination of lymphomatoid papulosis: an equivalent of limited plaque mycosis fungoides type of cutaneous T-cell lymphoma. J Am Acad Dermatol 2007; 57:1005.
  60. Torrelo A, Colmenero I, Hernández A, Goiriz R. Persistent agmination of lymphomatoid papulosis. Pediatr Dermatol 2009; 26:762.
  61. Hsu YJ, Su LH, Hsu YL, et al. Localized lymphomatoid papulosis. J Am Acad Dermatol 2010; 62:353.
  62. González-López MA, González-Vela Mdel C, Caballero C, et al. Localized lymphomatoid papulosis. Int J Dermatol 2015; 54:e98.
  63. Chaudhari PR, Emanuel P, Levitt J. Type B follicular lymphomatoid papulosis. Cutis 2010; 85:307.
  64. Kato N, Matsue K. Follicular lymphomatoid papulosis. Am J Dermatopathol 1997; 19:189.
  65. Deroo-Berger MC, Skowron F, Ronger S, et al. Lymphomatoid papulosis: a localized form with acral pustular involvement. Dermatology 2002; 205:60.
  66. Barnadas MA, López D, Pujol RM, et al. Pustular lymphomatoid papulosis in childhood. J Am Acad Dermatol 1992; 27:627.
  67. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118:4024.
  68. Pulitzer M, Ogunrinade O, Lin O, Steinherz P. ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient. J Cutan Pathol 2015; 42:182.
  69. Sasaki K, Sugaya M, Fujita H, et al. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation. Br J Dermatol 2004; 150:1202.
  70. Kadin ME, Pinkus JL, Pinkus GS, et al. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol 2008; 32:1421.
  71. Xue D, Li X, Ren Y, et al. Primary Cutaneous Anaplastic Large Cell Lymphoma With Positive ALK Expression and a Rapidly Progressive Cutaneous Nodule. Int J Surg Pathol 2015; 23:333.
  72. ten Berge RL, Snijdewint FG, von Mensdorff-Pouilly S, et al. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol 2001; 54:933.
  73. Yang S, Khera P, Wahlgren C, et al. Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature. Am J Clin Dermatol 2011; 12:203.
  74. Su LD, Schnitzer B, Ross CW, et al. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. J Cutan Pathol 1997; 24:597.
  75. Kadin ME, Sako D, Berliner N, et al. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood 1986; 68:1042.
  76. Lamant L, Pileri S, Sabattini E, et al. Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Haematologica 2010; 95:449.
  77. Rodríguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, et al. TCR-γ expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol 2013; 37:375.
  78. Parveen Z, Thompson K. Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas. Arch Pathol Lab Med 2009; 133:303.
  79. Magaña M, Massone C, Magaña P, Cerroni L. Clinicopathologic Features of Hydroa Vacciniforme-Like Lymphoma: A Series of 9 Patients. Am J Dermatopathol 2016; 38:20.
  80. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002; 10:7.
  81. Takata K, Hong ME, Sitthinamsuwan P, et al. Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia. Am J Surg Pathol 2015; 39:1.
  82. Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA. Peripheral T-cell lymphoma--not otherwise specified. Crit Rev Oncol Hematol 2011; 79:321.
  83. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:5496.
  84. Werner B, Massone C, Kerl H, Cerroni L. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol 2008; 35:1100.
  85. Kempf W, Kazakov DV, Palmedo G, et al. Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases. Am J Surg Pathol 2012; 36:1021.
  86. Jung J, Levin EC, Jarrett R, et al. Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 2011; 147:992.
  87. Saeed SA, Bazza M, Zaman M, Ryatt KS. Cefuroxime induced lymphomatoid hypersensitivity reaction. Postgrad Med J 2000; 76:577.
  88. Fukamachi S, Sugita K, Sawada Y, et al. Drug-induced CD30+ T cell pseudolymphoma. Eur J Dermatol 2009; 19:292.
  89. Nathan DL, Belsito DV. Carbamazepine-induced pseudolymphoma with CD-30 positive cells. J Am Acad Dermatol 1998; 38:806.
  90. Leinweber B, Kerl H, Cerroni L. Histopathologic features of cutaneous herpes virus infections (herpes simplex, herpes varicella/zoster): a broad spectrum of presentations with common pseudolymphomatous aspects. Am J Surg Pathol 2006; 30:50.
  91. Oflazoglu E, Simpson EL, Takiguchi R, et al. CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity. Eur J Dermatol 2008; 18:41.
  92. Lipozencić J, Bobek D, Jakić-Razumović J. The presence of surface CD30 on T cells in atopic dermatitis. Acta Dermatovenerol Croat 2003; 11:145.
  93. Cavagni G, Caffarelli C, Facchetti F, et al. Cutaneous CD30+ cells in children with atopic dermatitis. Int Arch Allergy Immunol 2000; 121:224.
  94. Dummer W, Rose C, Bröcker EB. Expression of CD30 on T helper cells in the inflammatory infiltrate of acute atopic dermatitis but not of allergic contact dermatitis. Arch Dermatol Res 1998; 290:598.
  95. Massi D, Trotta M, Franchi A, et al. Atypical CD30+ cutaneous lymphoid proliferation in a patient with tuberculosis infection. Am J Dermatopathol 2004; 26:234.
  96. Kadin ME. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology (Williston Park) 2009; 23:1158.
  97. Zelenetz AD. Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia. J Natl Compr Canc Netw 2014; 12:797.
  98. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34:470.
  99. Bruijn MS, Horváth B, van Voorst Vader PC, et al. Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. Br J Dermatol 2015; 173:1319.
  100. Newland KM, McCormack CJ, Twigger R, et al. The efficacy of methotrexate for lymphomatoid papulosis. J Am Acad Dermatol 2015; 72:1088.
  101. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007; 20:216.
  102. Shen S, O'Brien T, Yap LM, et al. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1.
  103. Volkenandt M, Kerscher M, Sander C, et al. PUVA-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child. Arch Dermatol 1995; 131:1094.
  104. Hoetzenecker W, Guenova E, Hoetzenecker K, et al. Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy. Eur J Dermatol 2009; 19:646.
  105. Errichetti E, Piccirillo A, Ricciuti F, Ricciuti F. Steroid-Resistant Localized Lymphomatoid Papulosis Treated with Local Bath-PUVA Therapy. Indian J Dermatol 2013; 58:163.
  106. Calzavara-Pinton P, Venturini M, Sala R. Medium-dose UVA1 therapy of lymphomatoid papulosis. J Am Acad Dermatol 2005; 52:530.
  107. Sanchez NP, Pittelkow MR, Muller SA, et al. The clinicopathologic spectrum of lymphomatoid papulosis: study of 31 cases. J Am Acad Dermatol 1983; 8:81.
  108. Perna AG, Jones DM, Duvic M. Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. Clin Lymphoma 2004; 5:190.
  109. Rodrigues M, McCormack C, Yap LM, et al. Successful treatment of lymphomatoid papulosis with photodynamic therapy. Australas J Dermatol 2009; 50:129.
  110. Kontos AP, Kerr HA, Malick F, et al. 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides. Photodermatol Photoimmunol Photomed 2006; 22:168.
  111. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 2003; 206:142.
  112. Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine therapy for lymphomatoid papulosis. Arch Dermatol 1985; 121:1410.
  113. Duvic M, Tetzlaff MT, Gangar P, et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 2015; 33:3759.
  114. Van Neer FJ, Toonstra J, Van Voorst Vader PC, et al. Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group. Br J Dermatol 2001; 144:351.
  115. Martorell-Calatayud A, Hernández-Martín A, Colmenero I, et al. [Lymphomatoid papulosis in children: report of 9 cases and review of the literature]. Actas Dermosifiliogr 2010; 101:693.
  116. de Souza A, Camilleri MJ, Wada DA, et al. Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol 2009; 61:993.
  117. Yip L, Darling S, Orchard D. Lymphomatoid papulosis in children: experience of five cases and the treatment efficacy of methotrexate. Australas J Dermatol 2011; 52:279.